NCT05401110招募中1 期
IIT2021-12-Reckamp-Osi105: Phase I Study of Osimertinib With Carotuximab in Advanced, EGFR-mutated Non-Small Cell Lung Cancer
Karen Reckamp, MD, MS5 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2023年9月15日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 60
- 试验地点
- 5
- 主要终点
- The number of adverse events and dose-limiting toxicities to find the Recommended Phase 2 Dose (RP2D) of combination of osimertinib with carotuximab in treatment of advanced, EGFR-mutated non-small cell lung cancer.
研究概览
简要总结
The purpose of this study is to examine the combination of osimertinib and carotuximab to assess the safety and find the recommended dose for treatment of advanced EGFR-mutated non-small cell lung cancer (NSCLC). Safety and tolerability will be measured by the number of dose-limiting toxicities, according to National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE) Version 5, to find the maximum tolerated dose. The secondary objectives include evaluating the rate of objective response rate, duration of response, progression-free survival, and disease control rate, along with assessing biomarkers through tumor tissue and circulating tumor DNA.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Stage IV or recurrent/metastatic non-squamous NSCLC that harbors an EGFR activating mutation (Exon 21 L858R, Exon 19 deletion, Exon 18 G719X, Exon 21 L861Q, etc). Local testing for EGFR mutations is acceptable provided it was performed in a CLIA certified lab.
- •Part I: Progressive disease on at least one prior EGFR TKI
- •Part II, Cohort 1: Progressive disease on osimertinib or other prior EGFR TKIs
- •Part II, Cohort 2: Receiving osimertinib as front line treatment for less than 12 weeks. Persistent ctDNA with EGFR mutation between weeks 6-12 from the start of osimertinib treatment.
- •Age at least 18
- •Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0-2
- •Archival tissue from a biopsy performed after progression of disease on previous EGFR TKI or willing to consent for a fresh tumor biopsy.
- •Measurable disease by RECIST 1.
- •Patients with untreated brain metastases are allowed provided that the patient is clinically asymptomatic and stable.
- •Patients must have completed prior chemotherapy ≥ 3 weeks or radiotherapy ≥ 2 weeks prior to receiving study drugs.
- •If the subject's most recent line of therapy is treatment with osimertinib, then all adverse events must be resolved to Grade 2 or better
- •If the subject's most recent line of therapy is any other treatment than osimertinib, then all Adverse Events must be resolved to grade 1 or better, with the exception of fatigue, alopecia and neuropathy (which must resolve to CTCAE grade 2).
- •Adequate organ function
- •Women of childbearing potential and men must agree to use adequate contraception while on study.
- •Written informed consent obtained from subject and ability for subject to comply with the requirements of the study.
排除标准
- •Past medical history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis requiring steroid treatment, or any evidence of clinically active interstitial lung disease.
- •Small cell lung cancer histology.
- •Other prior malignancy that might interfere with study endpoints per opinion of the investigator.
- •Prior exposure to carotuximab or any CD105 targeted antibody.
- •Any major surgical procedure within 2 weeks of starting therapy.
- •Patients must not have a history of uncontrolled or poorly-controlled hypertension defined as SBP > 150 mmHg or DBP > 90 mmHg within 28 days prior to enrollment.
- •Active bleeding or pathologic conditions that carries a high bleeding risk (e.g. gastric ulcers).
- •Use of thrombolytics within 10 days prior to the first day of carotuximab.
- •Known hypersensitivity to Chinese hamster ovary products or other recombinant human, chimeric, or humanized antibodies.
- •A known diagnosis of Osler-Weber-Rendu syndrome.
- •Ascites or pericardial or pleural effusion requiring external drainage procedures.
- •New evidence of leptomeningeal disease.
- •Acute cardiovascular event within the past 6 months.
- •Pregnancy or breastfeeding.
研究组 & 干预措施
Osimertinib with Carotuximab
Experimental
干预措施: Carotuximab (Drug)
Osimertinib with Carotuximab
Experimental
干预措施: Osimertinib (Drug)
结局指标
主要结局
The number of adverse events and dose-limiting toxicities to find the Recommended Phase 2 Dose (RP2D) of combination of osimertinib with carotuximab in treatment of advanced, EGFR-mutated non-small cell lung cancer.
时间窗: 4 weeks
The number of adverse events are graded by NCI CTCAE v5.0. The number of these dose-limiting toxicities (DLTs) experienced within the first treatment cycle (28 days) will be assessed to determine the RP2D.
次要结局
- Objective response rate(Assessed from baseline until the date of first documented progression, which is the end of treatment (EOT), assessed up to 2 years.)
- Biomarkers using tumor tissue and serial ctDNA for mutations.(From baseline until disease progression, or death, whichever came first. Assessed up to 2 years.)
- Disease control rate(Assessed from baseline until EOT, up to 2 years.)
- Progression free survival.(Assessed from the time of treatment initiation (C1D1) until first documentation of progression, or death due to any cause, whichever came first. Assessed up to 2 years. One treatment cycle is 28 days.)
- Duration of response(From baseline to first documentation of PD or death, whichever came first. Assessed up to 2 years.)
- Biomarkers of response to the combination using tumor tissue and serial ctDNA.(From baseline until disease progression, or death, whichever came first. Assessed up to 2 years.)
研究者
Karen Reckamp, MD, MS
Director, Division of Medical Oncology
Cedars-Sinai Medical Center
研究点 (5)
Loading locations...
相似试验
已完成
不适用
A Phase Ib study of osimertinib with ramucirumab in EGFR mutated lung adenocarcinoma patients. (LY3009806-IIT-01)To assess the efficacy and toxicity of Osimertinib plus ramucirumabJPRN-UMIN000030142Wakayama Medical University6
进行中（未招募）
2 期
A Phase 2 Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung CancerNon-small Cell Lung CancerNCT03392246Dana-Farber Cancer Institute25
已完成
1 期
Osimertinib and Bevacizumab as Treatment for EGFR-mutant Lung CancersEGFR-mutant Lung CancersNon-small Cell Lung CancerNCT02803203Memorial Sloan Kettering Cancer Center49
已完成
1 期
A phase I study of osimertinib with bevacizumab and randomized phase II study of osimertinib with or without bevacizumab in EGFR mutated, T790M positive patients who had progressed EGFR-TKIs. (WJOG8715L)ung CancerJPRN-UMIN000023761West Japan Oncology Group87
进行中（未招募）
1 期
A Study of the Combination of Osimertinib, Platinum and Etoposide for Patients With Metastatic EGFR Mutant Lung CancersLung CancerNCT03567642Memorial Sloan Kettering Cancer Center11